论文部分内容阅读
目的观察麝香保心丸联合阿托伐他汀对急性冠脉综合征(ACS)患者的临床治疗效果及其作用机理。方法选用60例确诊为急性冠脉综合症(ACS)患者随机分为对照组和治疗组。对照组30例给以阿托伐他汀等常规西药治疗;治疗组30例给以麝香保心丸加西药常规治疗,两组患者均连续服药8周;服药前后分别测定两组患者的血浆CRP、LDL-C、FIB的水平,将两组结果进行比较。结果治疗组及对照组患者治疗后血浆CRP、LDL-C、FIB水平较治疗前皆明显降低(P<0.05)。治疗组治疗后较对照组治疗后血浆CRP、FIB明显降低(P<0.05)。结论麝香保心丸联合阿托伐他汀治疗急性冠脉综合征(ACS)临床疗效确切显著,值得临床推广应用。
Objective To observe the therapeutic effect and the mechanism of “Shexiang Baoxin Pill” and “atorvastatin” on patients with acute coronary syndrome (ACS). Methods Sixty patients diagnosed with acute coronary syndrome (ACS) were randomly divided into control group and treatment group. 30 cases in the control group were given routine western medicine such as atorvastatin, 30 cases in the treatment group were treated with “Shexiang Baoxin Pill” and western medicine routinely for 8 weeks. Before and after taking the medicine, the plasma CRP, LDL-C, FIB levels, the two sets of results were compared. Results The plasma levels of CRP, LDL-C and FIB in treatment group and control group were significantly lower than those before treatment (P <0.05). The plasma CRP and FIB in the treatment group were significantly lower than those in the control group after treatment (P <0.05). Conclusion Shexiangbaoyin Pill combined with atorvastatin has definite and significant curative effect in treating acute coronary syndrome (ACS), which is worthy of clinical application.